FDA told CelestaPro its website sells unapproved, misbranded injectable botulinum toxin drugs, including "Nabota 200 Unit", to U.S. consumers.
What happened
FDA reviewed the website www.celestapro.com rather than conducting an inspection. FDA found the site offering injectable botulinum toxin drug products for sale to U.S. consumers, including a product marketed as "Nabota 200 Unit" that lists "Hyperhidrosis" as an application area. FDA said these are unapproved new drugs with no FDA-approved application and that their labeling lacks adequate directions for use, making them misbranded.
What FDA found
The website offers botulinum toxin drugs that FDA has never approved, so selling them breaks the law.
FD&C Act sections 301(d) and 505(a) [21 U.S.C. §§ 331(d), 355(a)]The drug labeling does not give directions a layperson could safely follow, which makes the drug misbranded.
FD&C Act section 502(f)(1) [21 U.S.C. § 352(f)(1)]; 21 CFR 201.5The drugs are not exempt from the adequate-directions requirement because they are not approved in the U.S.
21 CFR 201.115(a)By offering these drugs for sale to U.S. consumers, the website causes misbranded drugs to enter interstate commerce.
FD&C Act section 301(a) [21 U.S.C. § 331(a)]
What FDA wants
FDA asks CelestaPro to stop offering unapproved and misbranded drugs for sale to U.S. consumers and to review its websites, labels and promotional materials. The company must reply in writing within 15 working days describing the steps taken and how it will prevent repeat violations.
Who should pay attention
- med spas and aesthetic clinics that buy injectables online
- distributors and wholesalers sourcing botulinum toxin outside authorized channels
- consumers buying prescription injectables from websites
This is a summary. Read the original letter on fda.gov.